Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice

Pharmacological Reports

Volumn 57, Issue 6, 2005, Pages 755-760

  Biała, Grazyna ^a   Budzyńska, Barbara ^a   Kruk, Marta ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antinociception; Mecamylamine; Mice; Naloxone; Nicotine; Withdrawal

Indexed keywords

MECAMYLAMINE; MORPHINE; NALOXONE; NICOTINE TARTRATE; OPIATE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; ATTENUATION; CHOLINERGIC SYSTEM; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; HOT PLATE TEST; JUMPING; MALE; MASTICATION; MOUSE; NONHUMAN; PTOSIS; REFLEX; TOBACCO DEPENDENCE; TREMOR; WET DOG SHAKES; WITHDRAWAL SYNDROME;

EID: 33645661281     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Araki H, Kawakami KY, Jin C, Suemaru K, Kitamura Y, Nagata M, Futagami K et al.: Nicotine attenuates place aversion induced by naloxone in single-dose, morphine-treated rats. Psychopharmacology, 2004, 17, 398-404.
2. Balfour DJ: The effects of nicotine on brain neurotransmitter systems. Pharmacol Ther, 1982, 16, 269-282.
3. Berrendero F, Kieffer BL, Maldonado R: Attenuation of nicotine-induced antinociception, rewarding effects and dependence in μ-opioid receptor knock-out mice. J Neurosci, 2002, 22, 10935-10940.
4. Biała G: Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents. Pol J Pharmacol, 2003, 55, 327-335.
5. Biała G, Weglińska B: Calcium channel antagonists attenuate cross-sensitization to the locomotor effects of nicotine and ethanol in mice. Pol J Pharmacol, 2004, 56, 391-397.
6. Biala G, Welińska B: Calcium channel antagonists attenuate cross-sensitization to the rewarding and/or locomotor effects of nicotine, morphine and MK-801. J Pharm Pharmacol, 2004, 56, 1021-1028.
7. Dani JA: Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry, 2001, 49, 166-174.
8. Di Chiara G: Role of dopamine in behavioral actions of nicotine related to addiction. Eur J Pharmacol, 2000, 393, 295-314.
9. Eddy NB, Leimbach D: Synthetic analgesics. II. Dithienyl-butenyl- and dithienyl-butylamines. J Pharmacol Exp Ther, 1953, 107, 385-393.
10. Ginawi OT: Morphine analgesia in normal and alloxanized mice. Arch Int Pharmacodyn Ther, 1992, 318, 13-20.
11. Hildebrand BE, Nomikos GG, Hertel P, Schilstrom B, Svensson TH: Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats display a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res, 1998, 779, 214-225.
12. Houdi AA, Pierzchala K, Marson L, Palkovits M, Van Loon GR: Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides, 1991, 12, 161-166.
13. Iwamoto ET, Marion L: Adrenergic, serotonergic and cholinergic components of nicotinic antinociception in rats. J Pharmacol Exp Ther, 1993, 265, 777-789.
14. Malin DH: Nicotine dependence. Studies with a laboratory model. Pharmacol Biochem Behav, 2001, 70, 551-559.
15. Malin DH, Lake JR, Carter VA, Cuningham JS, Wilson OB: Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology, 1993, 112, 339-342.
16. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB: Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav, 1992, 43, 779-784.
17. Mansour A, Fox CA, Akil H, Watson SJ: Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci, 1995, 18, 22-29.
18. O'Callaghan JP, Holtzman SG: Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure. J Pharmacol Exp Ther, 1975, 192, 497-505.
19. Stolerman IP, Shoaib M: The neurobiology of tobacco addiction. Trends Pharmacol Sci, 1991, 12, 467-473.
20. Tome AR, Izaguirre V, Rosario LM, Cena V, Gonzales-Garcia G: Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromaffin cells. Brain Res, 2001, 903, 62-65.
21. Watkins SS, Koob GF, Markou A: Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tobacco Res, 2000, 2, 19-37.
22. Watkins SS, Stinus L, Koob GF, Markou A: Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther, 2000, 292, 1053-1064.
23. Wewers ME, Dhatt RK, Snively TA, Tejwani GA: The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkephalin levels in rats. Brain Res, 1999, 107-113.
24. Wonnacott S: Presynaptic nicotinic ACh receptors. Trends Neurosci, 1997, 20, 92-98.
25. Zarrindast MR, Barghi-Lashkari S, Shafzadeh M: The possible cross-tolerance between morphine- and nicotine-induced hypothermia in mice. Pharmacol Biochem Behav, 2001, 68, 283-289.
26. Zarrindast MR, Farzin D: Nicotine attenuates naloxone-induced jumping behavior in morphine-dependent mice. Eur J Pharmacol, 1996, 298, 1-6.
27. Zarrindast MR, Khoshayand MR, Shafaghi B: The development of cross-tolerance between morphine and nicotine in mice. Eur Neuropsychopharmacol, 1999, 9, 227-233.
28. Zarrindast MR, Nami AB, Farzin D: Nicotine potentiates morphine antinociception: a possible cholinergic mechanism. Eur Neuropsychopharmacol, 1996, 6, 127-133.